DK3532603T3 - Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion - Google Patents
Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion Download PDFInfo
- Publication number
- DK3532603T3 DK3532603T3 DK18707915.7T DK18707915T DK3532603T3 DK 3532603 T3 DK3532603 T3 DK 3532603T3 DK 18707915 T DK18707915 T DK 18707915T DK 3532603 T3 DK3532603 T3 DK 3532603T3
- Authority
- DK
- Denmark
- Prior art keywords
- immune response
- virus infection
- bifidobacterium longum
- respiratory virus
- advantageous modulation
- Prior art date
Links
- 241001608472 Bifidobacterium longum Species 0.000 title 1
- 229940009291 bifidobacterium longum Drugs 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158564 | 2017-02-28 | ||
| EP17158567 | 2017-02-28 | ||
| PCT/EP2018/054914 WO2018158306A1 (en) | 2017-02-28 | 2018-02-28 | Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3532603T3 true DK3532603T3 (da) | 2020-12-07 |
Family
ID=61521511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18707915.7T DK3532603T3 (da) | 2017-02-28 | 2018-02-28 | Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11529381B2 (da) |
| EP (1) | EP3532603B1 (da) |
| JP (1) | JP7055814B2 (da) |
| KR (1) | KR20190123267A (da) |
| CN (1) | CN110352237B (da) |
| AU (1) | AU2018227020B2 (da) |
| BR (1) | BR112019017940A2 (da) |
| CA (1) | CA3054099A1 (da) |
| DK (1) | DK3532603T3 (da) |
| ES (1) | ES2834950T3 (da) |
| MX (1) | MX2019010143A (da) |
| RU (1) | RU2768030C2 (da) |
| WO (1) | WO2018158306A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201010941A (en) * | 2008-05-27 | 2010-03-16 | Rev Renewable Energy Ventures Inc | Silicon containing halogenide, method for producing the same, and use of the same |
| WO2018209308A1 (en) * | 2017-05-12 | 2018-11-15 | The Regents Of The University Of California | Treating and detecting dysbiosis |
| JP2019167327A (ja) * | 2018-03-26 | 2019-10-03 | 森永乳業株式会社 | ビフィドバクテリウム属細菌を有効成分とする、ｉｉｉ型インターフェロン産生促進用組成物 |
| AR119031A1 (es) * | 2019-05-28 | 2021-11-17 | Aybar Ecotechnologies Corp | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma |
| EP4117697A1 (en) * | 2020-03-13 | 2023-01-18 | PrecisionBiotics Group Limited | Bifidobacterium longum |
| CN111529703B (zh) * | 2020-06-17 | 2023-09-15 | 湖南循天然营养有限公司 | 一种组合物及其制备方法与在制备免疫佐剂中的应用 |
| WO2023120547A1 (ja) * | 2021-12-22 | 2023-06-29 | 株式会社明治 | 二次性感染症の予防又は発症リスクを低減するための組成物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1598457A (en) | 1977-03-22 | 1981-09-23 | Glaxo Lab Ltd | Process for the preparation of a fraction containing peptidoglycan material from streptomyces griseus |
| DE3024318A1 (de) | 1980-06-27 | 1982-01-28 | Chemisches Laboratorium Dr. Karl Richter GmbH, 1000 Berlin | Kosmetische mittel |
| RU2151606C1 (ru) | 1998-07-09 | 2000-06-27 | Российский государственный медицинский университет | Штамм бактерий bifidobacterium longum z4 для приготовления бактерийных препаратов, нормализующих микрофлору при нарушениях микробиоценоза влагалища |
| PE20030284A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de bifidobacterium |
| RU2216588C1 (ru) | 2002-05-17 | 2003-11-20 | Государственное учреждение Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского | Штамм bifidobacterium longum я2, используемый для получения кисломолочных, ферментированных и неферментированных пищевых продуктов, заквасок, гигиенических и косметических средств, биологически активных добавок и бактерийных препаратов |
| CN1183960C (zh) | 2003-02-27 | 2005-01-12 | 四川大学 | 双歧杆菌细胞壁蛋白在制药中的应用 |
| JP2007169200A (ja) | 2005-12-21 | 2007-07-05 | Morinaga Milk Ind Co Ltd | インフルエンザ感染予防のための医薬及び飲食品 |
| RU2314341C1 (ru) | 2006-07-13 | 2008-01-10 | Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Штамм bifidobacterium longum гв-15, используемый для получения кисломолочных, ферментированных и неферментированных пищевых продуктов, заквасок, гигиенических и косметических средств, биологически активных добавок и бактерийных препаратов |
| WO2008053444A2 (en) | 2006-11-01 | 2008-05-08 | The Procter & Gamble Company | Treating a respiratory condition with bifidobacterium |
| RU2466185C2 (ru) * | 2007-03-28 | 2012-11-10 | Элиментари Хелт Лимитед | ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum |
| JP5538209B2 (ja) * | 2007-03-28 | 2014-07-02 | アリメンタリー・ヘルス・リミテッド | プロバイオティック性のビフィドバクテリウム菌株 |
| BRPI0811451A2 (pt) * | 2007-05-04 | 2014-11-04 | Alimentary Health Ltd | Exopolissacarídeo |
| CA2713525A1 (en) * | 2008-02-06 | 2009-08-13 | The Procter & Gamble Company | Compositions methods and kits for enhancing immune response to a respiratory condition |
| CA2716923A1 (en) * | 2008-03-17 | 2009-09-24 | The Procter & Gamble Company | User-customizable dosing system |
| FR2937547B1 (fr) | 2008-10-28 | 2012-11-09 | Oreal | Utilisation d'un lysat de microorganisme pour le traitement des peaux grasses |
| EP2289527B1 (en) | 2009-08-25 | 2018-02-21 | Nestec S.A. | Bifidobacterium longum and functional GI disorders |
| FI20096058A0 (fi) | 2009-10-13 | 2009-10-13 | Valio Oy | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä |
| ES2610829T3 (es) * | 2009-11-11 | 2017-05-03 | Alimentary Health Limited | Cepa de Bifidobacterium |
| ES2595444T3 (es) * | 2009-11-11 | 2016-12-30 | Alimentary Health Limited | Cepa de Bifidobacterium probiótica |
| EP2611484A4 (en) | 2010-09-02 | 2016-03-09 | Sipnose Ltd | DEVICE FOR NASAL ADMINISTRATION |
| EP2455092A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
| CN102321187B (zh) | 2011-08-15 | 2013-04-17 | 内蒙古双奇药业股份有限公司 | 一种从长双歧杆菌nq-1501中提取完整肽聚糖的方法 |
| US20130165470A1 (en) * | 2011-12-21 | 2013-06-27 | The Procter & Gamble Company | Methods for Detecting and Treating Rhinovirus Infection |
| WO2015021530A1 (en) | 2013-08-12 | 2015-02-19 | Mansel Griffiths | Antiviral methods and compositions comprising probiotic bacterial molecules |
| WO2015140299A1 (en) * | 2014-03-20 | 2015-09-24 | Universiteit Antwerpen | Oronasopharyngeal probiotics |
| RS58492B1 (sr) | 2014-07-16 | 2019-04-30 | Depofarma S P A | Parijetalna frakcija od propionibacterium granulosum koja ima imunomodulirajuće dejstvo |
| US10668117B2 (en) * | 2015-01-27 | 2020-06-02 | Dupont Nutrition Biosciences Aps | Immunomodulatory composition comprising bifidobacteria |
| EP3268017A1 (en) | 2015-03-09 | 2018-01-17 | Bioimmunizer SAGL | Anti-age composition comprising a combination of antioxidant agents in association with bifidobacteria and cell walls isolated from probiotics |
| WO2017032897A1 (en) * | 2015-08-27 | 2017-03-02 | Alimentary Health Limited | Use of bifidobacterium longum and an exopolysaccharide produced thereby |
| JP6637725B2 (ja) | 2015-10-28 | 2020-01-29 | ビオフェルミン製薬株式会社 | ウイルス感染症の予防及び／又は治療剤 |
| IT201600091033A1 (it) | 2016-09-08 | 2018-03-08 | Bioimmunizer Sagl | Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti. |
| US11590179B2 (en) | 2017-02-28 | 2023-02-28 | Precisionbiotics Group Limited | Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection |
| JPWO2018168449A1 (ja) | 2017-03-17 | 2020-01-16 | 国立大学法人東北大学 | ペプチドグリカン認識タンパク質産生促進用組成物 |
-
2018
- 2018-02-28 ES ES18707915T patent/ES2834950T3/es active Active
- 2018-02-28 CN CN201880014451.7A patent/CN110352237B/zh active Active
- 2018-02-28 WO PCT/EP2018/054914 patent/WO2018158306A1/en unknown
- 2018-02-28 RU RU2019128539A patent/RU2768030C2/ru active
- 2018-02-28 BR BR112019017940A patent/BR112019017940A2/pt unknown
- 2018-02-28 CA CA3054099A patent/CA3054099A1/en active Pending
- 2018-02-28 MX MX2019010143A patent/MX2019010143A/es unknown
- 2018-02-28 AU AU2018227020A patent/AU2018227020B2/en active Active
- 2018-02-28 JP JP2019546824A patent/JP7055814B2/ja active Active
- 2018-02-28 KR KR1020197024317A patent/KR20190123267A/ko not_active Application Discontinuation
- 2018-02-28 DK DK18707915.7T patent/DK3532603T3/da active
- 2018-02-28 US US16/489,141 patent/US11529381B2/en active Active
- 2018-02-28 EP EP18707915.7A patent/EP3532603B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019017940A2 (pt) | 2020-05-19 |
| RU2768030C2 (ru) | 2022-03-23 |
| CN110352237B (zh) | 2023-01-10 |
| US20200000859A1 (en) | 2020-01-02 |
| KR20190123267A (ko) | 2019-10-31 |
| WO2018158306A8 (en) | 2019-04-25 |
| WO2018158306A1 (en) | 2018-09-07 |
| EP3532603B1 (en) | 2020-09-09 |
| EP3532603A1 (en) | 2019-09-04 |
| AU2018227020B2 (en) | 2023-08-17 |
| AU2018227020A1 (en) | 2019-08-29 |
| JP7055814B2 (ja) | 2022-04-18 |
| US11529381B2 (en) | 2022-12-20 |
| ES2834950T3 (es) | 2021-06-21 |
| RU2019128539A (ru) | 2021-03-30 |
| CA3054099A1 (en) | 2018-09-07 |
| JP2020508672A (ja) | 2020-03-26 |
| CN110352237A (zh) | 2019-10-18 |
| RU2019128539A3 (da) | 2021-07-01 |
| MX2019010143A (es) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3532603T3 (da) | Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion | |
| DK3390441T3 (da) | Antistoffer til neutralisering af human immundefekt virus | |
| DK3552615T3 (da) | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer | |
| DK3597646T3 (da) | Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion | |
| DK3827845T3 (da) | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf | |
| DK3359564T3 (da) | Antistoffer til potent neutralisering af hepatitis B-virus og anvendelser deraf | |
| DK3169340T3 (da) | Kombination af onkolytisk virus med immun-checkpoint-modulatorer | |
| MA46904A (fr) | Administration virale de néo-antigènes | |
| DK3043865T3 (da) | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion | |
| DK3400293T3 (da) | Modificeret onkolytisk virus | |
| DK3584252T3 (da) | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3364993T3 (da) | Fremgangsmåder til behandling af angelman syndrom | |
| DK3558024T3 (da) | Fremstilling af beta-lactoglobulinpræparater | |
| DK3291679T3 (da) | Ændring af mikrobielle populationer og modificering af mikrobiota | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
| DK3684377T3 (da) | Fremgangsmåder til behandling af hepatitis-b-infektion | |
| DK3262071T3 (da) | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater | |
| DK3036258T3 (da) | Immunreceptormodulering til behandling af cancer og virusinfektioner | |
| DK3197489T3 (da) | Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion | |
| DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
| EA201691945A1 (ru) | Антитела к гемагглютинину вируса гриппа типа b и способы их применения | |
| DK3285756T3 (da) | Formuleringer af l-ornithinphenylacetat | |
| SG10201913958QA (en) | Modulation of hepatitis b virus replication |